Coronavirus (COVID-19) vaccine adverse reactions

A weekly report covering adverse reactions to approved COVID-19 vaccines

Documents

COVID-19 vaccine Pfizer analysis print

This file may not be suitable for users of assistive technology.

Request an accessible format.

COVID-19 vaccine AstraZeneca analysis print

This file may not be suitable for users of assistive technology.

Request an accessible format.

COVID-19 vaccine brand unspecified analysis print

This file may not be suitable for users of assistive technology.

Request an accessible format.

Details

The MHRA has played an active role in responding to the coronavirus pandemic. In relation to COVID-19 vaccines, the MHRA has authorised their supply following a rigorous review of their safety, quality and efficacy. The clinical trials of COVID-19 vaccines have shown them to be effective and acceptably safe; however, as part of its statutory functions, the MHRA is responsible for monitoring these vaccines on an ongoing basis to ensure their benefits continue to outweigh any risks.

This is a requirement for all authorised medicines and vaccines in the UK. This monitoring strategy is continuous, proactive and based on a wide range of information sources, with a dedicated team of scientists reviewing information daily to look for safety issues or unexpected rare events.

This weekly report summarises information received via the Yellow Card scheme and will be published regularly to include other safety investigations carried out by the MHRA under the COVID-19 Vaccine Surveillance Strategy.

This report covers the period 9 December 2020 to 21 March 2021.

Published 5 February 2021
Last updated 1 April 2021